Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients - Wikidata - awgldk - TriplyDB

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

http://www.wikidata.org/entity/Q33885497

about

Crystal structure and its bearing towards an understanding of key biological functions of EpCAM Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.Clinical Pharmacology and Translational Aspects of Bispecific Antibodies Editors' pick 2010.Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.Histological study of the biodynamics of iron oxide nanoparticles with different diameters Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Catumaxomab: in malignant ascites.Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Challenges and approaches for the development of safer immunomodulatory biologics.The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.Clinical pharmacology of bispecific antibody constructs.Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer.Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.Advances in ovarian cancer therapy.Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.Emerging classes of armed antibody therapeutics against cancer ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds

P2860

Q27694818-805ACEF4-5252-4589-B5C0-C0E970500F74 Q30716340-D62F7F55-C199-4917-9C8C-CFDFFC85D39D Q33648086-D0EFCE39-E5A1-4EA2-838F-2E1CE3F1D86F Q34476042-30533A03-FE3E-4EFF-B353-E43B0BB449A8 Q35079157-B874CB55-3A59-4CA4-92EC-0C620C762D2A Q35153715-2AF6F342-5AF9-4C54-BF73-4F200AB1C5B8 Q37965555-C7B8B251-B6F1-4932-ACB5-5C085CA6AA65 Q38016957-24B06A0B-EF9F-464F-84A0-14393E449CE4 Q38022538-2F083D05-37C9-4FCB-885D-0205AA1CB2F6 Q38073792-5611E3A0-FDD5-4057-B5DB-29DE5FABB79D Q38093772-4D8ADFBF-59C3-440C-88CC-07682F3C64C7 Q38104263-B4969A6A-EA19-4B9D-A6E4-B913E4CAE1DE Q38364459-CB0F0093-9140-4FDF-891E-806E139EF5EE Q38903708-6B1FA3E2-59DC-463C-BC9B-3688D42F0A99 Q41489391-CF3FFACC-AA3A-4A89-B84C-BFBD4A8EB37B Q41741997-F1BF7269-26CF-420A-BBC5-E425C6F4A086 Q46118058-0FFD6275-CB5D-4BF8-9D75-85EA4118D1CA Q48104995-A3050AE7-792D-412C-B21C-E850B17F69E6 Q53487785-C5428231-75C3-417C-8904-BEA833BACA43 Q53564949-53C81282-CAAE-4F17-86C6-A58B3F06FE70 Q57911948-7009EF65-8D3A-4538-B024-C51F089AE12C Q58869554-18749AC9-5346-4737-A0AE-FEC15D0FD4C4

P2860

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

http://www.wikidata.org/entity/Q33885497

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@ast

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@en

type

label

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@ast

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@en

prefLabel

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@ast

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@en

P1433

Q33885497-7AA6BA08-F13B-463F-95FC-19EDBA41CFA7

P1476

Q33885497-DB3DF81D-083B-4C91-B75A-9F2E04A0363A

P2093

Q33885497-08730D9E-39B1-4F6B-A402-928D364FA2B1

Q33885497-3074C90D-7ADD-42A2-AF89-27ED0CC72EC7

Q33885497-68809F87-B4BF-4275-BE9B-D3E746E7FC6E

Q33885497-90AEB5E6-16F3-44FE-A80E-DA620AA36AE0

Q33885497-9BC70771-C044-4FD4-96E7-DA29F0EA6BCA

Q33885497-E59DF541-76C6-4398-A96C-E06BDF7981BB

Q33885497-E763741D-EBA9-491B-A7CB-EFE2AE08F6B0

Q33885497-EE67D49A-F0AD-4F52-B7D0-0660FBFC38CD

Q33885497-FEF70F97-B460-4EDA-BF38-2DBB72B48FD6

P2860

Q33885497-10BCDA47-23AF-4187-BCAC-2084010CA257

Q33885497-55457A39-64E5-4FC6-A683-349F63F8EC32

Q33885497-5B6C3F10-7AD4-4621-BE9A-092D85A1F421

Q33885497-64BEDEFA-73DE-4B59-BD82-1D01D1F9F695

Q33885497-68A7CB76-388F-436F-8DF8-F88E87E8B860

Q33885497-7C9EE923-CF02-456C-9A66-2F3E8E49A68B

Q33885497-84E9ED90-9B10-4E53-8164-57D09E75D9D0

Q33885497-85081382-B4EB-431E-8093-F5BEB3860BDB

Q33885497-9AB64B72-1B96-433C-8236-FAD82D1D1753

Q33885497-A37546E9-DD0A-4E4A-A950-E2CDAF929D45

P304

Q33885497-19C100D0-9101-4DBB-980D-F35BCE88F836

P31

Q33885497-4497EC96-FC20-47D3-967C-25A33637181B

P356

Q33885497-D4967484-709C-4CC5-B948-E50F0C2260C9

P407

Q33885497-8EDE6B8E-77C3-4D7B-9F3C-6C0A4161AAA6

P433

Q33885497-0E7173E8-32A3-4CA9-AA45-632AAF5741B4

P478

Q33885497-47770A6D-1267-4F8B-B7E8-7B70445B315E

P50

Q33885497-8916EDF5-B739-4C08-A725-1221EEFD99ED

P577

Q33885497-14385463-AB1E-4FB8-B609-E285E9F75B5D

P5875

Q33885497-7434E1FB-2B73-4A70-8E3C-5AA4C0738B76

P698

Q33885497-AF5FEBB2-A9EE-42FB-8503-7C3B410696BA

P932

Q33885497-ED16EBC0-8D7C-4B60-9A42-F0C270339A85

P356

J.1365-2125.2010.03635.X

P1433

British Journal of Clinical Pharmacology

P1476

Pharmacokinetics, immunogenici ...... dministered to cancer patients

@en

P2093

Alexander Burges

http://www.w3.org/2001/XMLSchema#string

Birgit Brandt

http://www.w3.org/2001/XMLSchema#string

Constantin Volovat

http://www.w3.org/2001/XMLSchema#string

Horst Lindhofer

http://www.w3.org/2001/XMLSchema#string

Jürgen Hess

http://www.w3.org/2001/XMLSchema#string

Markus Maria Heiss

http://www.w3.org/2001/XMLSchema#string

Michael Jäger

http://www.w3.org/2001/XMLSchema#string

Michael Kluge

http://www.w3.org/2001/XMLSchema#string

Peter Ruf

http://www.w3.org/2001/XMLSchema#string

P2860

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

Frequent EpCam protein expression in human carcinomas

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.

Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.

Antibody pharmacokinetics and pharmacodynamics.

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.

Malignant ascites: systematic review and guideline for treatment.

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

P304

617-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2010.03635.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Pauline Wimberger

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44689973

http://www.w3.org/2001/XMLSchema#string

P698

20565453

http://www.w3.org/2001/XMLSchema#string

P932

2878603

http://www.w3.org/2001/XMLSchema#string